Contact us

877-469-1TRM
424-208-8866

A Study of Chemotherapy and Ramucirumab vs. Chemotherapy Alone in Second Line Non-small Cell Lung Cancer Patients Who Received Prior First Line Platinum Based Chemotherapy

A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Prior Platinum-Based Therapy

The purpose of the study is to compare survival of patients who receive chemotherapy and ramucirumab vs. chemotherapy alone as second line treatment for non-small cell lung cancer after prior first line platinum based chemotherapy.

For more information, please visit ClinicalTrials.gov

Patient Population Investigational Product(s) Phase Status
Non Small Cell Lung Cancer Ramucirumab III Closed